Curevac Vaccine News. The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine dimming hopes that it could help fill the worlds great need. The jab developed with GSK has shown better results in early-phase animal trials and appears to elicit 10 times more antibodies than the first vaccine.
1 day agoCureVac NV. 1 day agoGermanys CureVac NV said it would shelve its most advanced Covid-19 vaccine and focus on a new version in the latest sign that efforts to develop vaccines against the virus are entering a. The jab developed with GSK has shown better results in early-phase animal trials and appears to elicit 10 times more antibodies than the first vaccine.
What happened Shares of CureVac NASDAQCVAC were tumbling 74 as of 11 am.
Reuters -CureVac NV said on Tuesday it will give up on its first-generation COVID-19 vaccine candidate and instead focus on collaborating with GSK to develop improved mRNA vaccine. 1 day agoBERLIN Reuters -CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA vaccine technology instead the. 1 day agoCureVac NV. The news triggered a dive in the stock.
